论文部分内容阅读
目的:研究出一种新的治疗早中期糖尿病肾病安全有效、使用方便的中医外治疗法。方法:将90例早中期糖尿病肾病患者分为3组,A组30例为通络宝联合早肾方外治组,B组30例为口服早肾方组,C组30例为常规西药治疗组。观察治疗前、治疗后相关指标,观察3组疗效。结果:3组患者临床症状、血糖、糖化血红蛋白、肾功能(血肌酐、血尿素氮)、24 h尿微量蛋白定量、中医症候积分等相关指标均有改善,差异具有统计学意义(P<0.01)。3组患者临床疗效比较,A组总有效率93.3%优于B组76.6%和C组63.3%,差异具有统计学意义(P<0.01)。结论:通络宝联合早肾方是治疗早中期糖尿病肾病安全有效、使用方便的中医外治疗法。
Objective: To study out a new treatment of early and mid-term diabetic nephropathy safe and effective, easy to use external treatment of traditional Chinese medicine. Methods: Ninety patients with early-stage diabetic nephropathy were divided into three groups: 30 cases in group A were treated with Tongluobao combined with Zishenfang, 30 cases in group B were oral Zushenfang, 30 cases in group C were treated by conventional western medicine group. Observed before treatment, after treatment related indicators, observed three groups curative effect. Results: The clinical symptoms, blood glucose, glycosylated hemoglobin, renal function (serum creatinine, blood urea nitrogen), 24-hour urinary microalbuminuria, TCM symptom scores and other related indicators all improved in the three groups (P <0.01 ). The clinical efficacy of the three groups of patients, the total effective rate 93.3% in group A was better than 76.6% in group B and 63.3% in group C, the difference was statistically significant (P <0.01). Conclusion: Tongluo Bao Zaoshen Prescription is a safe and effective method for the treatment of early-stage diabetic nephropathy.